The current financial score of Champions Oncology Inc is 8.37. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 13.84M, representing a year-over-year increase of 11.98%, while its net profit experienced a year-over-year increase of 63.65%.
The current valuation score of Champions Oncology Inc is 9.26. Its current P/E ratio is -29.04, which is -2894.00% below the recent high of 811.43 and -811.47% above the recent low of -264.71.
No earnings forecast score is currently available for Champions Oncology Inc. The Biotechnology & Medical Research industry's average is 8.10. The average price target is 12.00, with a high of 12.00 and a low of 12.00.
The current price momentum score of Champions Oncology Inc is 3.98. Currently, the stock price is trading between the resistance level at 5.40 and the support level at 4.72, making it suitable for range-bound swing trading.
The current institutional shareholding score of Champions Oncology Inc is 3.00. The latest institutional shareholding proportion is 47.97%, representing a quarter-over-quarter decrease of 7.89%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 1.05% of shares outstanding, with 0.19% increase in holdings.
The current risk assessment score of Champions Oncology Inc is 3.67. The company's beta value is 0.41. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.